Lykos concludes European Phase II study for PTSD
Lykos Therapeutics has completed a European Phase II study (MP18) evaluating midomafetamine (MDMA) capsules for post-traumatic stress disorder (PTSD). MP18 is an open-label, multicenter feasibility study of investigational MDMA capsules used in combination …